     DURBIN ANNOUNCES  3 5 MILLION FOR BLOOD SUBSTITUTE TO BE TESTED FOR POTENTIAL USE ON BATTLEFIELD                                                                                                                                                                                                                                                                                                                 1 3 2006                                                                                                                                                                            DURBIN ANNOUNCES  3 5 MILLION FOR BLOOD SUBSTITUTE TO BE TESTED FOR POTENTIAL USE ON BATTLEFIELD                                                                                                                                                                                                                                                                                                                  Tuesday  January 3  2006    MOUNT PROSPECT  IL      U S  Sen  Dick Durbin  D IL  today announced  3 5 million in federal funding for clinical trials of a synthetic blood substitute pioneered by Northfield Labs of Evanston   Critically injured patients  such as soldiers grievously wounded on the battlefield  will benefit if the blood substitute  known as PolyHeme  can be used as an alternative to human blood during emergency transfusions        This research has the potential to save lives     said Durbin      First responders will be better able to help injured persons with massive blood loss and surgeons will have another resource in the emergency room   PolyHeme could also help doctors in rural or remote settings where blood supplies for transfusions are limited        Durbin  a member of the Senate Appropriations Committee  helped secure the funding through the Department of the Defense Fiscal Year 2006 Appropriations bill  The project is included in the more than  280 million in federal funding Durbin secured for Illinois defense related facilities and projects this year     Currently  trauma victims in need of resuscitation are treated with the infusion of a solution that does not carry oxygen  such as salt water   Once the victim arrives at the hospital  Type O blood may be used if an urgent transfusion is required   Otherwise  it can take 45 minutes to an hour to obtain cross matched fully compatible blood for the victim   s specific blood type   PolyHeme is manufactured from human blood and provides oxygen carrying capacity   It is compatible with all blood types and thus can be used quickly in the treatment of seriously injured persons   PolyHeme also has a shelf life of over 12 months  whereas donated red blood cells only have a shelf life of 42 days     Northfield Laboratories is currently in phase III of the pivotal trials for PolyHeme  the only oxygen carrying blood substitute the U S  being used in pre hospital  transport and hospital settings   Approximately 25 Level I trauma centers throughout the nation are participating in the clinical trials   The Food and Drug Administration has approved the use of PolyHeme in clinical trials   If the trials are successful  PolyHeme will be closer to being licensed for use in civilian and military settings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      